What is the clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have atrial fibrillation?
The clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have atrial fibrillation has not yet been fully established. Studies have suggested that biomarker-based monitoring may be useful in the assessment and follow up of heart failure patients with atrial fibrillation, as well as in the diagnosis of the cause of the atrial fibrillation. In addition, cardiac MRI may be useful in determining the cause of the atrial fibrillation, and in assessing the state of the heart muscle and its function. Finally, echocardiography may be useful in evaluating the heart's structure and function, as well as in determining if the atrial fibrillation is causing any abnormalities or complications.